Geron Corporation GERN
Geron Corporation (Nasdaq: GERN) is a hematology drug developer. Its lead program, imetelstat (RYTELO), is in Phase 2 for lower-risk myelodysplastic syndromes (MDS). Its next catalyst on record is RYTELO: Availability in Germany (Q4 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: RYTELO — Availability in Germany (Q4 2026). 2 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| imetelstat (RYTELO) | lower-risk MDS with transfusion-dependent anemia | oligonucleotide-other | Approved |
| imetelstat | higher-risk MDS and acute myeloid leukemia | oligonucleotide-other | Phase 2 |
| imetelstat | frontline myelofibrosis (MF) | oligonucleotide-other | Phase 1 |
| imetelstat | relapsed/refractory acute myeloid leukemia | oligonucleotide-other | Phase 1 |
Recent results and decisions
- Oct 28, 2026discontinued Geron discontinues Phase 3 IMpactMF trial of imetelstat in relapsed/refractory myelofibrosis based on DMC recommendation that the trial was unlikely to meet its primary endpoint of overall survival.
The independent DMC advised Geron that the trial was unlikely to meet its primary endpoint of overall survival.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 hematology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.